Paratek Pharmaceuticals Inc (PRTK) Stock
PRTK is no longer traded. Paratek Pharmaceuticals was delisted from the Nasdaq in September 2023.
Prices on this page are historical; the last trade was September 20, 2023 at $2.23.
Paratek Pharmaceuticals stock price history
PRTK final trading statistics
- Final close
- $2.23
- Final trading day
- Sep 20, 2023
- Market cap at delisting
- $127.83M
- Shares outstanding
- 57.32M
- Final 52-week range
- $1.29 – $3.65
- Avg. volume (final 3 mo.)
- 658,835
- All-time high (split-adj.)
- $2506.58 · Jul 2014
- All-time low (split-adj.)
- $1.37 · Mar 2023
- Return since IPO
- -99.4%
- Beta
- 1.70
- Book value / share
- -$3.52
- Price / book
- -0.63
Paratek Pharmaceuticals annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2022 | $150.79M | -$63.6M | -$1.18 |
| FY2021 | $120.95M | -$59.1M | -$1.22 |
| FY2020 | $43.52M | -$116.3M | -$2.25 |
| FY2019 | $16.54M | -$128.8M | -$3.93 |
| FY2018 | $17.12M | -$112.4M | -$3.57 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Paratek Pharmaceuticals Inc
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.
Paratek Pharmaceuticals stock FAQ
What happened to Paratek Pharmaceuticals stock?
Paratek Pharmaceuticals stock was delisted from the Nasdaq. Its final close was $2.23 on September 20, 2023.
Is PRTK stock still trading?
No. PRTK was delisted from the Nasdaq in September 2023 and no longer trades on a U.S. exchange.
What was the last price of PRTK stock?
PRTK closed at $2.23 on its final trading day, September 20, 2023, for a market value of about $127.83M.
What were Paratek Pharmaceuticals's revenue and earnings in its last full fiscal year?
Paratek Pharmaceuticals reported revenue of $150.79M and net income of -$63.6M in fiscal 2022, its last full year as a public company.
When did Paratek Pharmaceuticals go public?
Paratek Pharmaceuticals Inc stock began trading on May 11, 2006.